| Catalog No. | Size | Price (USD) |
| 10704-MM01-50 | 50 µL | $147.96 |
| 10704-MM01-100 | 100 µL | $251.64 |
| 10704-MM01-200 | 200 µL | $355.32 |
General Information
| Product name | Anti-IFN-beta Antibody, Mouse Monoclonal |
| Validated applications | ELISA (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human IFN-beta No cross-reactivity in ELISA with Human IFNαG / IFN-Alpha G |
| Immunogen | Recombinant Human IFNB protein (Catalog#10704-H02H) |
| Preparation | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human IFN-beta (rh IFNB; Catalog#10704-H02H; NP_002167.1; Met 1-Asn 187). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
| Source | Monoclonal Mouse IgG1 Clone #4C2E1D2 |
| Purification | Protein A |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-IFB Antibody; Anti-IFF Antibody; Anti-IFN-beta Antibody; Anti-IFNB Antibody
Background Information
| Full Name | interferon, beta 1, fibroblast |
| Description | Interferons (IFNs) are natural glycoproteins belonging to the cytokine superfamily and are produced by the cells of the immune system of most vertebrates in response to challenges by foreign agents such as viruses, parasites, and tumor cells. Interferon-beta (IFN beta) is an extracellular protein mediator of host defense and homeostasis. IFN beta has well-established direct antiviral, antiproliferative, and immunomodulatory properties. Recombinant IFN beta is approved for the treatment of relapsing-remitting multiple sclerosis. The recombinant IFN beta protein has the theoretical potential to either treat or causes autoimmune neuromuscular disorders by altering the complicated and delicate balances within the immune system networks. It is the most widely prescribed disease-modifying therapy for multiple sclerosis (MS). Large-scale clinical trials have established the clinical efficacy of IFN beta in reducing relapses and slowing disease progression in relapsing-remitting MS. IFN beta therapy was shown to be comparably beneficial for opticospinal MS (OSMS) and conventional MS in Japanese. IFN beta is effective in reducing relapses in secondary progressive MS and may have a modest effect in slowing disability progression. In addition to the common antiviral activity, IFN beta also induces increased production of the p53 gene product which promotes apoptosis and thus has a therapeutic effect against certain cancers. The role of IFN-beta in bone metabolism could warrant its systematic evaluation as a potential adjunct to therapeutic regimens of osteolytic diseases. Furthermore, IFN beta might play a beneficial role in the development of chronic progressive CNS inflammation. |
| Tags |
|
| References |
|
title: Epigallocatechin gallate inhibited IFN-β induced MUC5AC overexpression in airway epithelial cells by modulating JAK1 mediated STAT1 and ERK pathways activation.
authors: Qingge Chen; Xiaodong Li; ...; Zhenhua Ni
journal: Biochemical pharmacology
date: 2025-06-23
pmid: 40562128
doi: 10.1016/j.bcp.2025.117077
cited_by_count: 0
techniques: Lysis; Purification; cDNA Synthesis
bioz_score: 94
